Aug 23 (Reuters) - Eli Lilly's ( LLY ) treatment for
early Alzheimer's is expected to be blocked for use by Britain's
National Health Service (NHS), The Telegraph reported on Friday.
The drug donanemab would be rejected by the National
Institute for Health and Care Excellence (NICE), which decides
what drugs are available on the NHS, the newspaper reported
citing insiders.
(Reporting by Nilutpal Timsina in Bengaluru)